ClinicalTrials.gg
RecruitingNCT06830863Updated Oct 13, 2026

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

A Phase 1/2 interventional study of ATR04-484 and Vehicle in EGFR Inhibitor-associated Rash, sponsored by Azitra Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Azitra Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Oct 13, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 24 studies in Exanthema with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Exanthema · United States.

Planned enrollment
5th of 18
32 · median 14
Started
2025
with 1 other
Phase 1/2
2 of 24
1 open now
Registered
22nd of 24
by date
Lead sponsor
1 of 24
Azitra Inc.

Among the 24 studies in Exanthema with a site in United States, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 1/2, and was the 22nd registered.

Exanthema

68 studies on the registry are indexed under Exanthema; 11 are open to participants now.

Browse Exanthema studies →

Open to participants now

4 of the 24 studies in Exanthema with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Exanthema studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Exanthema with a site in United States, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will:

  • Apply ATR04-484 or vehicle daily for 28 days
  • Visit the clinic periodically for evaluation and sample collection
Read the detailed description

This is a multicenter, randomized, blinded, vehicle-controlled Phase 1/2 trial of topically applied ATR04-484 in adult patients with moderate to severe EGFRi-related non-infected dermal toxicity affecting the face. The neck, chest, back, and other areas may also be affected.

The safety, bioavailability, pharmacodynamics (PD), and preliminary effect of ATR04-484 (at a single concentration) will be compared to that of its vehicle, in 2 patient cohorts. In each cohort, eligible patients will be randomized (3:1 ratio) to ATR04-484 or its vehicle. The initial cohort (n = 8) will receive a single 4 g application of the study drug to the face, chest, and back, followed by a 7-day observation period. Upon completion of this observation period, the patients in this cohort may continue in the study with daily applications of study drug for an additional 28 days. Following a safety observation period, a subsequent cohort (n = 24) may be enrolled and will receive a 4 g application of the study drug once daily for 28 days. Each cohort will be followed for 28 days after the last application of study drug.

Clinical assessments of treatment effect will be evaluated at each area that has received a full application of study drug (coverage of all lesional surfaces). The primary endpoint is safety and tolerability. Secondary endpoints including clinical efficacy, including: (1) the severity of the dermal toxicity using a 5-point regional assessment scale, based on modified CTCAE descriptors for skin toxicity (including a score of 0 for clear or unaffected skin through 4 for severely affected skin); (2) numeric rating scales for pruritus and pain; and (3) a quality-of-life assessment (Functional Assessment of Cancer Therapy-EGFRI 18 [FACT-EGFRI 18]). Bioavailability of ATR04-484 will also be assessed.

03

Conditions studied

  • EGFR Inhibitor-associated Rash

Browse trials for

Keywords

  • EGFR
  • acneiform
  • EGFR inhibitor-associated rash
  • EGFRi
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years of age
  • Currently treated with an FDA-approved EGFRi, KRASi, or MEKi (or other medications in the pathway, if approved by the Medical Monitor) for the treatment of cancer with or without concurrent chemotherapy, or for neurofibromatosis, and expected to continue treatment with the medication through the study treatment period
  • Has Grade 2 or 3 non-infected moderate to severe dermal toxicity affecting the face (the neck, chest, back and other areas may also be affected); Grade 1 toxicity may be permitted in up to 25% of enrolled patients

Exclusion criteria

Exclusion Criteria:

  • Significant skin disease other than EGFRi-related dermal toxicity
  • Treatment with topical mid- to high-potency topical , or topical antibiotics or antibacterial washes on the face, neck, chest, or back within 7 days prior to baseline; treatment with systemic antibiotics or systemic corticosteroids within 7 days prior to baseline
  • Residing with an person residing with them in the same dwelling from the baseline visit through 2 weeks after the treatment period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    ATR04-484

    Topically applied ATR04-484

    Drug: ATR04-484

  • Placebo comparator
    Vehicle

    Topically applied vehicle

    Drug: Vehicle

Interventions

  • DrugATR04-484

    ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use

    Also known as: ATR-04

  • DrugVehicle

    Topically applied vehicle.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Treatment-emergent adverse events

    Time frame: 57 days

Secondary outcomes

  1. Severity of dermal toxicity

    Investigator assessment of dermal toxicity using a 5-point regional assessment scale, based on modified CTCAE descriptors for skin toxicity (including a score of 0 for clear or unaffected skin through 4 for severely affected skin).

    Time frame: 57 days

  2. Pruritus

    Patient reported via numeric rating scale for reflective (24 hour) pruritus

    Time frame: 57 days

  3. Quality-of-life assessment

    Patient reported using Functional Assessment of Cancer Therapy-EGFRI 18 \[FACT-EGFRI 18\]

    Time frame: 57 days

Other outcomes

  1. Bioavailability of ATR04-484

    The bioavailability of SE484 will be assessed by qPCR

    Time frame: 57 days

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jan 2027 → Jul 2027 and completion Feb 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 17, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Jul 15, 2027was Jan 2027
CompletionEst.
Sep 15, 2027was Feb 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 15, 2027→Jul 15, 2027
Oct 13, 2026
Study completion
Feb 15, 2027→Sep 15, 2027
Oct 13, 2026
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • AddedCurrently treated with an FDA-approved EGFRi, KRASi, or MEKi (or other medications in the pathway, if approved by the Medical Monitor) for the treatment of cancer with or without concurrent chemotherapy, or for neurofibromatosis, and expected to continue treatment with the medication through the study treatment period
  • EditedHas Grade 2 or 3 non-infected moderate to severe EGFRi-related dermal toxicity affecting the face (the neck, chest, back and other areas may also be affected); Grade 1 toxicity may be permitted in up to 25% of enrolled patients
Exclusion criteria
  • EditedTreatment with topical mid- to high-potency topical corticosteroids, or topical antibiotics or antibacterial washes on the face, neck, chest, or back within 147 days prior to baseline; treatment with systemic antibiotics or systemic corticosteroids within 147 days prior to baseline
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Yale University School of Medicine · New Haven, United StatesContact •••2270→•••2270
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Jan 15, 2027→Jul 15, 2027
    Study completion Feb 15, 2027→Sep 15, 2027
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • AddedCurrently treated with an FDA-approved EGFRi, KRASi, or MEKi (or other medications in the pathway, if approved by the Medical Monitor) for the treatment of cancer with or without concurrent chemotherapy, or for neurofibromatosis, and expected to continue treatment with the medication through the study treatment period
    • EditedHas Grade 2 or 3 non-infected moderate to severe EGFRi-related dermal toxicity affecting the face (the neck, chest, back and other areas may also be affected); Grade 1 toxicity may be permitted in up to 25% of enrolled patients
    Exclusion criteria
    • EditedTreatment with topical mid- to high-potency topical corticosteroids, or topical antibiotics or antibacterial washes on the face, neck, chest, or back within 147 days prior to baseline; treatment with systemic antibiotics or systemic corticosteroids within 147 days prior to baseline
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Yale University School of Medicine · New Haven, United StatesContact •••2270→•••2270
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06830863
Lead sponsor
Azitra Inc.
Collaborators
Prosoft Clinical
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Aug 25, 2025
Primary completion
Jul 15, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Mary Spellman, MD
Contact
spellman@azitrainc.com
415-652-7962

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion